The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel
Open accessAbstract
BACKGROUND: Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown. METHODS: We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary intervention: 1079 patients were randomly assigned in a double-blind manner to receive abciximab and 1080 patients to receive placebo. All patients were pretreated with a 600-mg dose of clopidogrel at least two hours before the procedure. The primary end point of the trial was the composite of death, myocardial infarction, and urgent target-vessel revascularization within 30 days after randomization. RESULTS: The incidence of the primary end point was 4 percent (45 patients) in the abciximab group, as compared with 4 percent (43 patients) in the placebo group (relative risk, 1.05; 95 percent confidence interval, 0.69 to 1.59; P=0.82). Most adverse events were myocardial infarctions: the incidence was 4 percent (40 patients) in the abciximab group and 4 percent (41 patients) in the placebo group (P=0.91). Twelve patients (1 percent) in the abciximab group and eight patients (1 percent) in the placebo group had major bleeding complications (P=0.37). Profound thrombocytopenia occurred in 10 patients (1 percent) in the abciximab group but in none in the placebo group (P=0.002). CONCLUSIONS: Our data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Self-citationSchömig, A., Neumann, F.-J., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.-M., Richardt, G., Alt, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341702 · Cited by 2,028
Self-citation(1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362401 · Cited by 1,883
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Letter: Grading of angina pectoris.
Campeau, L. (1976) · Circulation · doi:10.1161/circ.54.3.947585 · Cited by 1,601
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Identification of the platelet ADP receptor targeted by antithrombotic drugs
Hollopeter, G., Jantzen, H.-M., Vincent, D., Li, G., England, L., Ramakrishnan, V., Yang, R.-B., Nurden, P., Nurden, A., Julius, D., et al. (2001) · Nature · doi:10.1038/35051599 · Cited by 1,423
Ellis, S. G., Vandormael, M. G., Cowley, M. J., DiSciascio, G., Deligonul, U., Topol, E. J., & Bulle, T. M. (1990) · Circulation · doi:10.1161/01.cir.82.4.1193 · Cited by 1,350
Epistent Investigators, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)06113-3 · Cited by 1,346
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,162
Topol, E. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)85010-1 · Cited by 1,095
Topol, E. J., Moliterno, D. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Cohen, D. J., Cohen, E. A., Bertrand, M., Neumann, F.-J., Stone, G. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442502 · Cited by 677
Self-citationSmith, S. C., Dove, J. T., Jacobs, A. K., Kennedy, J. W., Kereiakes, D., Kern, M. J., Kuntz, R. E., Popma, J. J., Schaff, H. V., Williams, D. O., et al. (2001) · Circulation · doi:10.1161/01.cir.103.24.3019 · Cited by 608
Quinn, M. J., & Fitzgerald, D. J. (1999) · Circulation · doi:10.1161/01.cir.100.15.1667 · Cited by 496
Scientific and therapeutic advances in antiplatelet therapy
Bhatt, D. L., & Topol, E. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd985 · Cited by 407
MÜLLER, I., SEYFARTH, M., RÜDIGER, S., WOLF, B., POGATSA-MURRAY, G., SCHÖMIG, A., & GAWAZ, M. (2001) · Heart · doi:10.1136/heart.85.1.92 · Cited by 405
Self-citationAbciximab reduces mortality in diabetics following percutaneous coronary intervention
Bhatt, D. L., Marso, S. P., Lincoff, A. M., Wolski, K. E., Ellis, S. G., & Topol, E. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00650-6 · Cited by 336
The Antiplatelet Effects of Ticlopidine and Clopidogrel
Sharis, P. J., Cannon, C. P., & Loscalzo, J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-5-199809010-00009 · Cited by 322
Frontiers in Interventional Cardiology
Topol, E. J., & Serruys, P. W. (1998) · Circulation · doi:10.1161/01.cir.98.17.1802 · Cited by 247
Eumann, N., Astrati, A. D. K., Chühlen, H. E. S., Lasini, R. U. B., Adamitzky, M. A. H., Alter, H. A. W., Va, E., Ichardt, G. E. R., Chmitt, C. L. S., & U, K. U. (1996) · Cited by 124
Single-dose pharmacodynamics of clopidogrel
Wallis, D. E., Lewis, B. E., & Walenga, J. M. (2000) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1016/s1053-0770(00)90075-2 · Cited by 117
Helft, G., Osende, J. I., Worthley, S. G., Zaman, A., Rodriguez, O. J., Lev, E. I., Farkouh, M. E., Fuster, V., Badimon, J. J., & Chesebro, J. H. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.10.2316 · Cited by 88
Steinhubl, S. R., Lauer, M. S., Mukherjee, D., Moliterno, D. J., Lincoff, A. M., Ellis, S. G., & Topol, E. J. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00376-3 · Cited by 81
Berger, P. B., & Steinhubl, S. R. (2002) · Circulation · doi:10.1161/01.cir.0000035924.70846.20 · Cited by 46
Self-citation
Cited by
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Self-citationWriting Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Metadata
- Authors
- Kastrati, A., Mehilli, J., Schühlen, H., Dirschinger, J., Dotzer, F., ten Berg, J. M., Neumann, F.-J., Bollwein, H., Volmer, C., Gawaz, M., Berger, P. B., & Schömig, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-15
- Volume
- 350
- Issue
- 3
- Pages
- 232-238
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2059136191
- Cited by
- 567
- References
- 25
- FWCI
- 51.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.